Researchers look for surrogate endpoints to predict early benefit of cancer drugs
 

Great hopes are always placed in new cancer therapies. However, whether new surgical techniques, drugs or radiation therapies actually prolong the life of cancer patients, or even cure them, can often only be reliably assessed after several years' of testing. Researchers are therefore looking for proxy markers that after initiation of cancer therapy can reliably predict as quickly as possible whether the treatment has a benefit.

More...